Study record · Orforglipron
ATTAIN-1: orforglipron for obesity treatment
Mean weight change was -7.5%, -8.4% and -11.2% versus -2.1% with placebo.
Key result
Mean weight change was -7.5%, -8.4% and -11.2% versus -2.1% with placebo.
Study details
Study designMultinational randomized, double-blind, placebo-controlled trial
PhasePhase III
PopulationAdults with obesity without diabetes
Sample size3127
RouteOral
Regimen / exposure6, 12 or 36 mg once daily in the trial formulation
Duration72 weeks
ComparatorPlacebo
Primary endpoint / questionPercent change in body weight
Safety resultGastrointestinal events were most common; discontinuation due to adverse events was higher with orforglipron.
Key limitationsTrial doses/formulation must not be silently converted into current commercial tablet strengths.
Registry / identifierNCT05869903